As part of Hatch-Waxman litigation, CRA was asked to assess commercial success of Ofirmev, an injectable acetaminophen product for peri-operative use. The CRA team assessed the success of Ofirmev in the United States and another embodiment of the patents in the Big 5 European countries. CRA’s expert,. Dr. Gregory Bell, opined on commercial success as a secondary indicia of non-obviousness and opined that there was a nexus to the patents. Ultimately, the court agreed with Dr. Bell’s assessment and found for commercial success.
12 CRA consultants named top IP professionals in the 2022 IAM Patent 1000
12 CRA consultants were recognized as leading patent professionals by Intellectual Asset Management (IAM). The IAM Patent 1000: The World’s Leading Patent...